Protocol Ledger

NCT05485948 · Phase II · ACTIVE NOT RECRUITING

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Interventional Phase II clinical trial protocol NCT05485948 sponsored by PharmaEssentia in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-08 Enrollment: 49 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05485948
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)49 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05485948
Protocol FieldVerified Registry Value
NCT IdentifierNCT05485948
Consolidated Lead SponsorPharmaEssentia
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment49 participants (ACTUAL)
Registered Start Date2021-10-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI